Clinical trial · Interventional
Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer
NCT01757366CI-TRIAL-00014148unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Safety and Efficacy of Ginsenoside Rg3 in Combination with First-line Chemotherapy in Advanced Gastric Cancer.The purpose of this study is to assess the safety of Ginsenoside Rg3 in advanced gastric cancer, and whether it improves the efficacy of first-line chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Self Efficacy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| First-line Chemotherapy | Drug | — | UNRESOLVED |
| Ginsenoside Rg3 plus First-line Chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- experimental
- description
- Ginsenoside Rg3 plus First-line Chemotherapy
- interventionNames
- Drug: Ginsenoside Rg3 plus First-line Chemotherapy
- type
- ACTIVE_COMPARATOR
- label
- Active Comparator
- description
- First-line Chemotherapy
- interventionNames
- Drug: First-line Chemotherapy
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 1 years
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent form 2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1; 3. Histologically or cytologically confirmed gastric cancer; 4. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) 5. Life expectancy of at least 3 months; Exclusion Criteria: 1. Received any prior treatment including Ginsenoside Rg3; 2. Active or uncontrolled infection; 3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; 4. Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.